Undetected lymph node metastases in presumed early stage NSCLC SABR patients

Alberto Cerra-Franco, Khalil Diab, Tim Lautenschlaeger

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Introduction: Stereotactic body radiation therapy (SBRT, also called stereotactic ablative body radiation SABR) is the treatment of choice for many patients with early-stage non-small cell lung cancer (NSCLC), including those who are unfit for surgery or refuse surgery. Areas covered: In an effort to develop optimal staging for the evaluation of SBRT candidates, we review the performance of available lymph node staging methods, as well as risk factors for lymph node involvement. Pubmed was searched to identify relevant literature. Current staging methods for NSCLC, including Positron Emission Tomography/Computed Tomography(PET/CT) and endobronchial ultra sound (EBUS), have limited sensitivities. Expert commentary: There are several factors, including primary tumor location, tumor size, and histology that are possibly associated with the sensitivity of PET/CT to detect mediastinal lymph node metastasis. Small lymph node metastases typically remain undetected by PET/CT. Therefore invasive nodal staging procedures are indicated for most presumed early-stage NSCLC patients, but these also have limited sensitivity. Occult lymph node metastasis is associated with adverse outcome in NSCLC. Moreover, there is overwhelming evidence that certain patients who have lymph node metastases detected at the time of surgery derive an overall survival benefit from adjuvant therapies. It remains to be determined if improved detection of lymph node metastases in SABR candidates can indeed improve prognosis.

Original languageEnglish (US)
Pages (from-to)869-875
Number of pages7
JournalExpert Review of Anticancer Therapy
Volume16
Issue number8
DOIs
StatePublished - Aug 2 2016

Fingerprint

Non-Small Cell Lung Carcinoma
Lymph Nodes
Neoplasm Metastasis
PubMed
Neoplasms
Histology
Radiotherapy
Radiation
Survival
Therapeutics
Positron Emission Tomography Computed Tomography

Keywords

  • CT
  • EBUS
  • EUS
  • non-small cell lung cancer
  • occult metastases
  • PET
  • SABR
  • SBRT
  • SBRT lymph node metastases
  • staging

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Undetected lymph node metastases in presumed early stage NSCLC SABR patients. / Cerra-Franco, Alberto; Diab, Khalil; Lautenschlaeger, Tim.

In: Expert Review of Anticancer Therapy, Vol. 16, No. 8, 02.08.2016, p. 869-875.

Research output: Contribution to journalReview article

Cerra-Franco, Alberto ; Diab, Khalil ; Lautenschlaeger, Tim. / Undetected lymph node metastases in presumed early stage NSCLC SABR patients. In: Expert Review of Anticancer Therapy. 2016 ; Vol. 16, No. 8. pp. 869-875.
@article{4b27ee3a3e81463e9e8c2653343b0bfe,
title = "Undetected lymph node metastases in presumed early stage NSCLC SABR patients",
abstract = "Introduction: Stereotactic body radiation therapy (SBRT, also called stereotactic ablative body radiation SABR) is the treatment of choice for many patients with early-stage non-small cell lung cancer (NSCLC), including those who are unfit for surgery or refuse surgery. Areas covered: In an effort to develop optimal staging for the evaluation of SBRT candidates, we review the performance of available lymph node staging methods, as well as risk factors for lymph node involvement. Pubmed was searched to identify relevant literature. Current staging methods for NSCLC, including Positron Emission Tomography/Computed Tomography(PET/CT) and endobronchial ultra sound (EBUS), have limited sensitivities. Expert commentary: There are several factors, including primary tumor location, tumor size, and histology that are possibly associated with the sensitivity of PET/CT to detect mediastinal lymph node metastasis. Small lymph node metastases typically remain undetected by PET/CT. Therefore invasive nodal staging procedures are indicated for most presumed early-stage NSCLC patients, but these also have limited sensitivity. Occult lymph node metastasis is associated with adverse outcome in NSCLC. Moreover, there is overwhelming evidence that certain patients who have lymph node metastases detected at the time of surgery derive an overall survival benefit from adjuvant therapies. It remains to be determined if improved detection of lymph node metastases in SABR candidates can indeed improve prognosis.",
keywords = "CT, EBUS, EUS, non-small cell lung cancer, occult metastases, PET, SABR, SBRT, SBRT lymph node metastases, staging",
author = "Alberto Cerra-Franco and Khalil Diab and Tim Lautenschlaeger",
year = "2016",
month = "8",
day = "2",
doi = "10.1080/14737140.2016.1199279",
language = "English (US)",
volume = "16",
pages = "869--875",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "8",

}

TY - JOUR

T1 - Undetected lymph node metastases in presumed early stage NSCLC SABR patients

AU - Cerra-Franco, Alberto

AU - Diab, Khalil

AU - Lautenschlaeger, Tim

PY - 2016/8/2

Y1 - 2016/8/2

N2 - Introduction: Stereotactic body radiation therapy (SBRT, also called stereotactic ablative body radiation SABR) is the treatment of choice for many patients with early-stage non-small cell lung cancer (NSCLC), including those who are unfit for surgery or refuse surgery. Areas covered: In an effort to develop optimal staging for the evaluation of SBRT candidates, we review the performance of available lymph node staging methods, as well as risk factors for lymph node involvement. Pubmed was searched to identify relevant literature. Current staging methods for NSCLC, including Positron Emission Tomography/Computed Tomography(PET/CT) and endobronchial ultra sound (EBUS), have limited sensitivities. Expert commentary: There are several factors, including primary tumor location, tumor size, and histology that are possibly associated with the sensitivity of PET/CT to detect mediastinal lymph node metastasis. Small lymph node metastases typically remain undetected by PET/CT. Therefore invasive nodal staging procedures are indicated for most presumed early-stage NSCLC patients, but these also have limited sensitivity. Occult lymph node metastasis is associated with adverse outcome in NSCLC. Moreover, there is overwhelming evidence that certain patients who have lymph node metastases detected at the time of surgery derive an overall survival benefit from adjuvant therapies. It remains to be determined if improved detection of lymph node metastases in SABR candidates can indeed improve prognosis.

AB - Introduction: Stereotactic body radiation therapy (SBRT, also called stereotactic ablative body radiation SABR) is the treatment of choice for many patients with early-stage non-small cell lung cancer (NSCLC), including those who are unfit for surgery or refuse surgery. Areas covered: In an effort to develop optimal staging for the evaluation of SBRT candidates, we review the performance of available lymph node staging methods, as well as risk factors for lymph node involvement. Pubmed was searched to identify relevant literature. Current staging methods for NSCLC, including Positron Emission Tomography/Computed Tomography(PET/CT) and endobronchial ultra sound (EBUS), have limited sensitivities. Expert commentary: There are several factors, including primary tumor location, tumor size, and histology that are possibly associated with the sensitivity of PET/CT to detect mediastinal lymph node metastasis. Small lymph node metastases typically remain undetected by PET/CT. Therefore invasive nodal staging procedures are indicated for most presumed early-stage NSCLC patients, but these also have limited sensitivity. Occult lymph node metastasis is associated with adverse outcome in NSCLC. Moreover, there is overwhelming evidence that certain patients who have lymph node metastases detected at the time of surgery derive an overall survival benefit from adjuvant therapies. It remains to be determined if improved detection of lymph node metastases in SABR candidates can indeed improve prognosis.

KW - CT

KW - EBUS

KW - EUS

KW - non-small cell lung cancer

KW - occult metastases

KW - PET

KW - SABR

KW - SBRT

KW - SBRT lymph node metastases

KW - staging

UR - http://www.scopus.com/inward/record.url?scp=84982994288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982994288&partnerID=8YFLogxK

U2 - 10.1080/14737140.2016.1199279

DO - 10.1080/14737140.2016.1199279

M3 - Review article

C2 - 27279087

AN - SCOPUS:84982994288

VL - 16

SP - 869

EP - 875

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 8

ER -